EOS IMAGING supported by a new contract in the United States

(AOF) – EOS imaging jumped 5.16% to 1.3 euros, supported by a new contract. The provider of 2D / 3D imaging and data solutions for orthopedics announced last night the installation of an EOS system, as part of the EOSone program, in the prestigious Cantor Spine Institute, a private orthopedic clinic located in Fort Lauderdale, Florida. For the medtech owned 13.4% by the Chinese Fosun, this new facility shows the increasing adoption of the EOS solution by private clinics, thanks to the EOSone program.

The EOSone program enables private practices to access EOS technology by integrating all of EOS 'orthopedic solutions into an offer designed specifically for private institutions that does not require an initial down payment from them. Featuring a streamlined funding model with an exam payment option, the EOSone program provides distinctive benefits to private centers and allows for better patient experience and operational efficiency in routine clinical care.

"EOS imaging continues to strengthen and enhance its portfolio of service solutions for its various customers, with the EOSone program being one example, and with this program we have expanded our offering to simplify access to our technology for private centers. so they can offer advanced imaging and surgical planning solutions, just like the world's leading hospitals, "said Mike Lobinsky, general manager of EOS imaging.

AOF – LEARN MORE

Pharmacy – Health

In 2018, mergers and acquisitions in the sector were close to $ 200 billion, a significant increase over 2017. And 2019 begins strongly with the recovery by Bristol-Myers Squibb (BMS) of biotech specialist Celgene of oncology, for 74 billion dollars. Together, they give birth to a giant with $ 33.3 billion in sales, the world leader in oncology (62% of its turnover) and in cardiovascular diseases.

Acquisitions are multiplying in biotechnology in response to the need of "Big Pharma" to renew their products. More than 71% of drugs in clinical development last year are from biotech, according to the American trade union, BIO. The Japanese Takeda has acquired the Irish Shire, for 81.7 billion dollars. For its part, Eli Lilly bought the biotech Loxo Oncology for $ 8 billion, just after GSK got hold of another American biotech, Tesaro.